Management of dyslipidemia in adults

American Family Physician

Volumn 57, Issue 9, 1998, Pages 2192-2204

  Ahmed, Syed M ^a   Clasen, Mark E ^a   Donnelly, John F ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIGITALIS; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FUROSEMIDE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LIFIBROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PHENOBARBITAL; PRAVASTATIN; PROPRANOLOL; QUESTRAN LITE; RESIN; SIMVASTATIN; TETRACYCLINE; THIAZIDE DIURETIC AGENT; THYROXINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ALCOHOL CONSUMPTION; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; CORONARY RISK; DIETARY FIBER; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ESTROGEN THERAPY; EXERCISE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GLUCOSE INTOLERANCE; GOUT; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER TOXICITY; LOW FAT DIET; MYOPATHY; PLASMAPHERESIS; REVIEW; WEIGHT REDUCTION;

ADULT; ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIETARY FATS; DIETARY FIBER; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; MIDDLE AGED; PATIENT EDUCATION; RISK FACTORS; TEACHING MATERIALS;

EID: 0032080052     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Superko HR, Krauss RM. coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
2. Philbin EF, Pearson TA. How does lipid-lowering therapy rapidly reduce ischemic events? J Myocard Ischemia 1994;6:13-8.
3. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet 1994;344:1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
6. Gibaldi M, Kradjan W. Treating elevated cholesterol levels: the great Satan in perspective. J Clin Pharmacol 1996;36:189-97.
7. Geurian KL. The cholesterol controversy. Ann Pharmacother 1996;30:495-500.
8. Jungnickel PW. Cholesterol-lowering therapy: is there really a controversy? Ann Pharmacother 1996;30:539-42.
9. LaRosa JC. Cholesterol lowering and morbidity and mortality. Curr Opin Lipidol 1995;6:62-5.
10. Gotto AM Jr. Lipid-regulating and antiatherosclerotic therapy: current options and future approaches. Cleve Clin J Med 1996;63:31-41.
11. Atkins D, Garber AM. When experts disagree: the cholesterol standoff, Patient Care 1996;30(20):62-91.
12. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II). Bethesda, Md: National Cholesterol Education Program, National Institutes of Health, National Heart, Lung, and Blood Institute, 1993; DHSS publication no. (NIH) 93-3095:5.
13. Schaefer EJ. Diagnosis and management of lipoprotein disorders. In: Rifkind BM, ed. Drug treatment of hyperlipidemia. New York: Dekker, 1991:17-52.
14. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34-42,94-103, 148-56,215-25, 273-81.
15. Oliver M, Poole-Wilson P, Shepherd J, Tikkanen MJ. Lower patients' cholesterol now [Editorial]. BMJ 1995;310:1280-1.
16. Yeshurun D, Gotto AM Jr. Hyperlipidemia: perspectives in diagnosis and treatment. South Med J 1995;88:379-91.
17. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
18. Blake GH, Triplett LC. Management of hypercholesterolemia. Am Fam Physician 1995;51:1157-66.
19. National Cholesterol Education Program. Cholesterol lowering in the patient with coronary heart disease. Bethesda, Md.: National Institutes of Health, National Heart, Lung, and Blood Institute, 1997; DHSS publication no. (NIH) 97-3794.
20. Anderson JW, Gustafson NJ. High-carbohydrate, high-fiber diet. Is it practical and effective in treating hyperlipidemia? Postgrad Med 1987;82(4):40-3,47-50,55.
21. Cohen JD, Pearson TA, Weart CW. Who really needs cholesterol-lowering drugs? Patient Care 1996;30(2):92-107.
22. Gotto AM Jr. Management of lipid and liprotein disorders. In: Gotto AM Jr, Pownall HJ, eds. Manual of lipid disorders. Baltimore: Williams & Wilkins, 1922.
23. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease, N Engl J Med 1995;332:512-21.
24. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
25. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilheimsen L, Wedel H, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandanavian Simvastatin Survival Study. Circulation 1996;93:1796-802.
26. Snyder S. Comparison of cholesterol-lowering regimens. Am Fam Physician 1990;42:761-8.
27. Breckenridge WC. The role of lipoproteins and apolipoproteins in prediction of coronary heart disease risk. Clin Invest Med 1990;13:196-201.
28. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-6.
29. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
30. Hunninghake DB, Peters JR. Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Am J Med 1987;83(Suppl 5B):44-9.
31. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987;93:9-20.
32. Smith DA. Hypercholesterolemia: putting the new expert panel guidelines to work for your patient. Consultant 1994;34:838-52.
33. Locker PK, Jungbluth GL, Francom SF, Hughes GS Jr. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group. Clin Pharm Ther 1995;57:73-88.
34. Bostorn AG, Cupples LA, Jenner JL, Ordovas JM, Seman U, Wilson PW, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996;276:544-8.
35. Chapman MJ, Huby T, Nigon F, Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis 1994;110(Suppl):S69-75.
36. Kinlay S, Dobson AJ, Heller RF, McElduff P, Alexander H, Dickeson J. Risk of primary and recurrent acute myocardial infarction from lipoprotein (a) in men and women. J Am Coll Cardiol 1996;28:870-5.
37. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.
38. Grodstein F, Stamper MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality, N Engl J Med 1997;336:1769-75.
39. Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennan KB. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997;157:1186-92.
40. Keller C. LDL-apheresis: results of longterm treatment and vascular outcome. Atherosclerosis 1991;86:1-8.
41. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.